Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Economy Hits Drugmaker Profits

Posted by Jane Akre
Friday, March 20, 2009 10:27 AM EST
Category: Major Medical, Protecting Your Family
Tags: Phamrmaceutical Industry, Drugs, Generics, Drug Profits, Zocor, Lipitor, Anti-Depressants, Narcotics

Sales of prescription drugs are up minimally 1.3 percent, a great decline from double-digit profits of the past.  


IMAGE SOURCE: ©iStockphoto/ pouring pills/ author: VisualField


The sale of prescription drugs isn’t what it used to be.

Sales in the U.S. rose just 1.3 percent in 2008, to $291 billion, according to information supplied by IMS Health Inc. The company gathers marketing data from drug companies. 

“It’s a new lower-growth environment than we’ve seen in the past, although some of the factors have been present for awhile,” says Diana Conmy with IMS.

The factors include the increased use of generic drugs, made to resemble the original when it goes off patent.  Other patients are apparently choosing to go without medical treatment, unable to afford private insurance or COBRA.

Prescription drug sales rose at a 3.8 percent growth in 2007 and eight percent in 2006. Previous years have seen double-digit growth.

Still the leader of the pack – lipid medicines that lower bad LDL cholesterol or raise good HDL cholesterol. Codeine and painkillers with narcotics followed with anti-depressants, two types of blood pressure drugs or ACE inhibitors and beta blockers rounded out the top five sales.

Just on the horizon is the sunsetting of patents for blockbuster drugs Lipitor (Pfizer); Plavix (Bristol-Myers Squibb); and Zyprexa (Lilly). All three drugs have patents that expire in two years.

The U.S remains the only country that does not regulate the price of prescription medications. Industry analysts fear that in an Obama administration, drugmakers may be forced to negotiate the prices of their name brand products. 

And diminishing profits are seeing mergers between previous drug rivals.

After shying away from acquisition, Merck has announced plans to acquire New Jersey drugmaker Schering –Plough for $41.1 billion. The merger will still be called Merck, and for the next two years will be headed by Merck Chief Executive, Richard Clark.

The deal echoes another one for two drug giants, Pfizer agreeing weeks ago to buy Wyeth for $68 billion.  #


Anonymous User
Posted by Joan Petty
Friday, March 20, 2009 12:16 PM EST

Merck, sold their generic drug manufacting operation to Mylan pharmaceutical Company in Morgantown, W. VA. With this sale came 6 Billion dollars price tag of cash payment to Merck and a agreement that Merck would transfer some of their personel and in turn Mylan would issue some stock to the Merck Co. Inc. Mylan is now the 3rd largest world wide generic drug manufacturing Co.
Merck has another tenical to take over another company buy out.

Posted by Daniel Haszard
Friday, March 20, 2009 1:16 PM EST

Eli Lilly is making positive PR over their $4 billion Zyprexa damages settlement while dragging their feet paying victims,many who are mentally challenged and less capable of advocating for themselves.
Daniel Haszard used Zyprexa for 4 years and got diabetes from it. www.zyprexa-victims.com

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes